Llama antibody fragments have good potential for application as HIV type 1 topical microbicides

AIDS Research and Human Retroviruses

Volumn 28, Issue 2, 2012, Pages 198-205

  Gorlani, Andrea ^a   Brouwers, Joachim ^b   McConville, Christopher ^c   Van Der Bijl, Pieter ^d   Malcolm, Karl ^c   Augustijns, Patrick ^b   Quigley, Anna Forsman ^e   Weiss, Robin ^e   De Haard, Hans ^a   Verrips, Theo ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

A 12; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LLAMA HEAVY CHAIN ANTIBODY FRAGMENT; MICROBICIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BINDING SITE; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; DRUG STORAGE; DRUG TRANSPORT; FREEZE DRYING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IMMUNOCOMPETENT CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SACCHAROMYCES CEREVISIAE; TABLET FORMULATION; VAGINA MUCOSA; VAGINA RING;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; ANTIBODY AFFINITY; CAMELIDS, NEW WORLD; CONTRACEPTIVE DEVICES, FEMALE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; SACCHAROMYCES CEREVISIAE; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84858027347     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0133     Document Type: Article

References (39)

1. 2008 Report on the global AIDS epidemic, 2008.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23):2209-2220.
3. Cutler B and Justman J: Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008;8(11):685-697.
4. Walker PR, Worobey M, Rambaut A, Holmes EC, and Pybus OG: Epidemiology: Sexual transmission of HIV in Africa. Nature 2003;422(6933):679. (Pubitemid 36514098)
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329(5996):1168-1174.
6. Larkin M: "Inactive" polymer is active against sexually transmitted diseases. Lancet 1999;354(9176):399.
7. Pearce-Pratt R and Phillips DM: Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod 1996;54(1):173-182. (Pubitemid 126506813)
8. Rusconi S,MoonisM,Merrill DP, et al.: Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996;40(1):234-236. (Pubitemid 26020755)
9. Ludovici DW, De Corte BL, Kukla MJ, et al.: Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett 2001;11(17):2235-2239. (Pubitemid 32781673)
10. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, and Parniak MA: Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997;71(4):3023-3030. (Pubitemid 27119946)
11. Balzarini J, Aquaro S, Perno CF, Witvrouw M, Holý A, and De Clercq E: Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)- adenine and 9-(2-phosphonylmethoxypropyl)- 2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem Biophys Res Commun 1996;219(2):337-341. (Pubitemid 26090906)
12. Skoler-Karpoff S, Ramjee G, Ahmed K, et al.: Efficacy of carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2009;372(9654):1977-1987.
13. Parren PW, Ditzel HJ, Gulizia RJ, et al.: Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 1995;9(6):6-11.
14. Lederman MM, Offord RE, and Hartley O: Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Immunol Rev 2006;6:371.
15. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al.: Naturally occurring antibodies devoid of light chains. Nature 1993;363(6428):446-448. (Pubitemid 23179389)
16. El Khattabi M, Adams H, Heezius E, et al.: Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: Prospects for therapeutic applications. Clin Vaccine Immunol 2006;13(10):1079-1086. (Pubitemid 44622533)
17. Roovers RC, Laeremans T, Huang L, et al.: Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother 2007;56(3):303-317. (Pubitemid 46035901)
18. Frenken LG, van der Linden RH, Hermans PW, et al.: Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol 2000;78(1):11-21. (Pubitemid 30084786)
19. Frenken LG, Hessing JG, Van den Hondel CA, and Verrips CT: Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms. Res Immunol 1998;149(6):589-599. (Pubitemid 29486829)
20. Thomassen YE, Meijer W, Sierkstra L, and Verrips CT: Large-scale production of VHH antibody fragments by Saccharomyces cerevisiae. Enzyme Microbial Technol 2002;30:273-278. (Pubitemid 34203834)
21. van de Laar T, Visser C, Holster M, et al.: Increased heterologous protein production by Saccharomyces cerevisiae growing on ethanol as sole carbon source. Biotechnol Bioeng 2007;96(3):483-494. (Pubitemid 46232354)
22. Forsman A, Beirnaert E, Aasa-Chapman MM, et al.: Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 2008;82(24):12069-12081.
23. Koh WW, Steffensen S, Gonzalez-Pajuelo M, et al.: Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1. J Biol Chem 2010;285(25):19116-19124.
24. Strokappe NM, Szynol A, Aasa-Chapman MMI, et al.: Llama antibody fragments recognizing various epitopes of CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. Manuscript in preparation.
25. Jahnichen S, Blanchetot C, Maussang D, et al.: CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci USA 2010;107(47):20565- 20570.
26. Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LG, and de Geus B: Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol 2000;37(10):579-590. (Pubitemid 32052527)
27. Owen DH and Katz DF: A vaginal fluid simulant. Contraception 1999;59(2):91-95. (Pubitemid 29244754)
28. Owen DH and Katz DF: A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl 2005;26(4):459-469. (Pubitemid 40847857)
29. Basson E, van der Bijl P, and van Eyk AD: Transvaginal diffusion of synthetic peptides. Eur J Inflam 2007;5:15-20. (Pubitemid 46779249)
30. van der Bijl P, van Eyk AD, van Zyl JM, Moll LM, Schols D, and Balzarini J: Diffusion of two potential anti-HIV microbicides across intact and de-epithelialised, human vaginal mucosa. Eur J Inflam 2008;6(1):17-23. (Pubitemid 351675968)
31. Fiscella K and Klebanoff MA: Are racial differences in vaginal pH explained by vaginal flora? Am J Obstet Gynecol 2004;191(3):747-750. (Pubitemid 39298103)
32. Shattock RJ and Moore JP: Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003;1:25.
33. Hinz A, Lutje Hulsik D, Forsman A, et al.: Crystal structure of the neutralizing llama V(HH) D7 and its mode of HIV-1 gp120 interaction. PloS one 2010;5(5):e10482.
34. Huang B, Guo J, Yi B, Yu X, Sun L, and Chen W: Heterologous production of secondary metabolites as pharmaceuticals in Saccharomyces cerevisiae. Biotechnol Lett 2008;30(7):1121-1137.
35. Romano J, Malcolm RK, Garg S, Rohan LC, and Kaptur PE: Microbicide delivery: Formulation technologies and strategies. Curr Opin HIV AIDS 2008;3(5):558-566.
36. Veazey RS, Shattock RJ, and Pope M: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9:343.
37. Klasse PJ, Shattock RJ, and Moore JP: Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med 2006;3:1501.
38. Hermeling S, Crommelin D, Schellekens H, and Jiskoot W: Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004;21(6):897-903. (Pubitemid 38870136)
39. Coppieters K, Dreier T, Silence K, et al.: Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 2006;54(6):1856-1866. (Pubitemid 43877935)